$26.35
Today
as of Sep 4, 16:53 ET
Last 30 days
Recent Press Releases & News
Pacira (PCRX) Up 6.9% Since Last Earnings Report: Can It Continue?
Pacira (PCRX) Q2 2026 Earnings Call Transcript
Is Pacira BioSciences (PCRX) Quietly Reframing Its Non‑Opioid Strategy Around PCRX‑201 Gene Therapy?
Overview
52-week range
$19
$28
85% of range
Avg surprise (last 2)
+0.7%
Avg reaction (last 1)
-1.1%
0% positive
Latest IV / EM
91%
EM ±14.2% · $28 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $0.12 | — | — | — | — | financials |
| Tue Mar 31, 2026 | Mar 2026 | $0.07 | — | — | — | — | financials |
| Tue Sep 30, 2025 | Sep 2025 | $0.12 | — | — | — | — | financials |
| Tue Aug 5, 2025 | Jun/2025 | $0.47 | $0.49 | -4.1% | — | — | earnings |
| Thu May 8, 2025 | Mar/2025 | $0.39 | $0.37 | +5.4% | — | -1.1% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-3.11 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $0.39 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $0.19 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $0.23 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $0.51 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $-0.43 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $192M | $177M | — | $180M | $181M | $169M | — | $169M |
| Cost of revenue | $44M | $36M | — | $34M | $41M | $34M | — | $39M |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $4M | $7M | — | $6M | $8M | $2M | — | $-140M |
| Net income | $5M | $3M | — | $5M | $-5M | $5M | — | $-143M |
| EPS (diluted) | $0.12 | $0.07 | — | $0.12 | $-0.11 | $0.10 | — | $-3.11 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $206M | $144M | $159M | $148M | $300M | $284M | $277M | $246M |
| Inventory | $135M | $150M | $153M | $158M | $148M | $134M | $125M | $112M |
| Total current assets | $615M | $515M | $548M | $563M | $746M | $760M | $745M | $690M |
| Total assets | $1.24B | $1.21B | $1.26B | $1.30B | $1.54B | $1.59B | $1.55B | $1.52B |
| Long-term debt | $363M | $368M | $372M | $377M | $580M | $583M | $384M | — |
| Total liabilities | $572M | $555M | $572M | $570M | $779M | $788M | $775M | $772M |
| Total equity | $672M | $654M | $693M | $727M | $758M | $799M | $778M | $750M |